Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hALK.CAR T Cells in Relapsed/Refractory High-risk Neuroblastoma
NCT06803875Phase 2Recruiting
- Sponsor
- ALKemist Bio
- Start
- Jan 2025
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of hALK CAR T cells in neuroblastoma, sponsored by ALKemist Bio. Started Jan 2025; status: recruiting.
02
Drugs
hALK CAR T cells
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT06803875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06803875.